Physician profile
Jennifer H Calnan
NPI 1508076027
$3,207.14
in general payments reported to CMS, 2019-2025
13 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Pediatrics (Optometrist) provider received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $141 · 2021: $207 · 2022: $1,869 · 2023: $209 · 2024: $350 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,949.35 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $276.25 | 2023-2024 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $228.43 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $168.80 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $153.63 | 2020-2025 | Tryptyr |
| Oyster Point Pharma, INC. | $148.20 | 2022-2024 | Tyrvaya |
| Glaukos Corporation | $67.19 | 2024-2025 | Istent Infinite, Photrexa |
| Dompe US, INC. | $66.79 | 2019-2022 | |
| Shire North American Group INC | $43.91 | 2019 | |
| Coopervision INC. | $35.62 | 2023-2024 | Myday Contact Lens, Misight Contact Lens |
| Novartis Pharmaceuticals Corporation | $32.16 | 2023 | |
| Allergan, INC. | $22.84 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2023 | Austedo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Calnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.